AU677309B2 - Purification of factor VII - Google Patents

Purification of factor VII Download PDF

Info

Publication number
AU677309B2
AU677309B2 AU64239/94A AU6423994A AU677309B2 AU 677309 B2 AU677309 B2 AU 677309B2 AU 64239/94 A AU64239/94 A AU 64239/94A AU 6423994 A AU6423994 A AU 6423994A AU 677309 B2 AU677309 B2 AU 677309B2
Authority
AU
Australia
Prior art keywords
fvii
buffer
purification
naci
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64239/94A
Other languages
English (en)
Other versions
AU6423994A (en
Inventor
Tony Jorgensen
Anders Hjelholt Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU6423994A publication Critical patent/AU6423994A/en
Application granted granted Critical
Publication of AU677309B2 publication Critical patent/AU677309B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
AU64239/94A 1993-03-31 1994-03-24 Purification of factor VII Ceased AU677309B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK93382A DK38293D0 (da) 1993-03-31 1993-03-31 Fremstilling af proteiner
DK382/93 1993-03-31
PCT/DK1994/000122 WO1994022905A1 (en) 1993-03-31 1994-03-24 Purification of factor vii

Publications (2)

Publication Number Publication Date
AU6423994A AU6423994A (en) 1994-10-24
AU677309B2 true AU677309B2 (en) 1997-04-17

Family

ID=8092871

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64239/94A Ceased AU677309B2 (en) 1993-03-31 1994-03-24 Purification of factor VII

Country Status (16)

Country Link
US (1) US5700914A (enExample)
EP (1) EP0691984A1 (enExample)
JP (1) JPH08508264A (enExample)
CN (1) CN1039231C (enExample)
AU (1) AU677309B2 (enExample)
CA (1) CA2159313A1 (enExample)
CZ (1) CZ253395A3 (enExample)
DK (1) DK38293D0 (enExample)
FI (1) FI954649A0 (enExample)
HU (1) HUT72712A (enExample)
IL (1) IL109164A0 (enExample)
NO (1) NO953883L (enExample)
PL (1) PL310887A1 (enExample)
TW (1) TW278079B (enExample)
WO (1) WO1994022905A1 (enExample)
ZA (1) ZA941956B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19538716A1 (de) * 1995-10-18 1997-04-24 Behringwerke Ag Verfahren zur Quantifizierung von aktiviertem Gerinnungsfaktor VII (FVIIa)
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
SI1308455T1 (sl) † 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2519020A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
DE602004025100D1 (de) * 2003-05-23 2010-03-04 Novo Nordisk Healthcare Ag Stabilisierung von proteinen in lösung
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ATE446768T1 (de) * 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
WO2005054275A2 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor vii solutions to remove virus
CA2549593C (en) * 2003-12-19 2014-02-11 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
AU2005318106B2 (en) * 2004-12-23 2011-11-03 Novo Nordisk Health Care Ag Reduction of the content of protein contaminants in compositions comprising a Vitamin K-dependent protein of interest
DE602006015907D1 (de) * 2005-01-14 2010-09-16 Bayer Healthcare Llc Verfahren zur reinigung von factor vii
EP1907540B1 (en) * 2005-07-22 2012-12-19 Bayer HealthCare LLC In-solution activation of factor vii
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
WO2007073486A2 (en) * 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII
BR112015008666B1 (pt) 2012-10-17 2020-04-07 Procter & Gamble produto extensível para tratamento dental e método de aplicação de um ativo para tratamento bucal
US11059857B2 (en) 2016-12-22 2021-07-13 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins

Also Published As

Publication number Publication date
HU9502846D0 (en) 1995-12-28
NO953883D0 (no) 1995-09-29
AU6423994A (en) 1994-10-24
CN1039231C (zh) 1998-07-22
PL310887A1 (en) 1996-01-08
CZ253395A3 (en) 1996-01-17
US5700914A (en) 1997-12-23
HUT72712A (en) 1996-05-28
TW278079B (enExample) 1996-06-11
ZA941956B (en) 1994-09-30
FI954649A7 (fi) 1995-09-29
IL109164A0 (en) 1994-06-24
FI954649L (fi) 1995-09-29
FI954649A0 (fi) 1995-09-29
CA2159313A1 (en) 1994-10-13
NO953883L (no) 1995-11-28
WO1994022905A1 (en) 1994-10-13
JPH08508264A (ja) 1996-09-03
CN1121723A (zh) 1996-05-01
EP0691984A1 (en) 1996-01-17
DK38293D0 (da) 1993-03-31

Similar Documents

Publication Publication Date Title
AU677309B2 (en) Purification of factor VII
US5580560A (en) Modified factor VII/VIIa
ES2263199T3 (es) Analogos del factor x con un sitio de ruptura de proteasa modificado.
CA1339815C (en) Modified factor vii/viia
US5225537A (en) Methods for producing hybrid phospholipid-binding proteins
US5516650A (en) Production of activated protein C
IL88559A (en) Vectors and compounds for direct expression of human activated C protein
JP4108761B2 (ja) Ｘ因子欠失突然変異体およびそのアナログ
Josic et al. Preparation of vitamin K-dependent proteins, such as clotting factors II, VII, IX and X and clotting inhibitor protein C
Zhang et al. Role of the hexapeptide disulfide loop present in the. gamma.-carboxyglutamic acid domain of human protein C in its activation properties and in the in vitro anticoagulant activity of activated protein C
Morita et al. Calcium binding to a human factor IXa derivative lacking γ-carboxyglutamic acid: evidence for two high-affinity sites that do not involve β-hydroxyaspartic acid
EP0323149B1 (en) Vectors and compounds for expression of zymogen forms of human protein C
RU2167936C2 (ru) Способ минимизации деградации активированного протеина с (варианты), стабилизированная композиция активированного протеина с
Yu et al. Construction, expression, and properties of a recombinant chimeric human protein C with replacement of its growth factor-like domains by those of human coagulation factor IX
US6010844A (en) Methods of preparing and recovering proteins
WO1991012320A1 (en) Activated protein c with truncated light chain
NZ545825A (en) Plasminogen activators having reduced lysine binding capacity
Mollerup et al. The use of RP‐HPLC for measuring activation and cleavage of rFVIIA during purification
CZ328594A3 (en) PURIFICATION OF CRINGL-CONTAINING PEPTIDES, PARTICULARLY t-PA
AIS A zyxwvutsrqponmlkjihgfedcb
MXPA99007768A (en) Factor x analogues with a modified protease cleavage site
JP2001514516A (ja) 活性化ビタミンｋ依存性血液因子およびその製造方法
MXPA99007817A (en) Factor x deletion mutants and analogues thereof